Mapping antithrombotic regimens in Multiple Myeloma patients
Official title: Real-World Mapping Antithrombotic Regimens in Multiple Myeloma Patients on Treatment (The MAMMOTH Study of the GIMEMA Working Party on Hemostasis and Thrombosis)
Run by Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT06028087 · Data updated 2026-11-12
This study looks at how different blood-thinning treatments help prevent blood clots in people with Multiple Myeloma over three years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 736 (estimated) |
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto Academic / other |
| Locations | 1 site (Roma) |
| Status | Recruiting |
| Started | March 10, 2025 |
| Main results expected | March 2030 |
| Study ends | March 2030 |
| Registry record updated | March 14, 2025 |
| Trial ID | NCT06028087 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have a new diagnosis of symptomatic Multiple Myeloma and are starting their first active treatment.
✕Probably not a fit
Patients who have experienced thrombosis within the last six months or are currently undergoing treatment initiated before the study will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the efficacy of various thromboprophylaxis methods in patients diagnosed with Multiple Myeloma. It will track patients over a three-year period, categorizing them into four cohorts based on the type of antithrombotic regimen they receive: no prophylaxis, antiplatelet agents, heparins, or oral anticoagulants. The study will take place within the GIMEMA network of Italian hematological centers, allowing for a comprehensive evaluation of real-world treatment outcomes. Patients will be monitored regardless of their disease stage or treatment type.
Why it matters
Potential benefit: If successful, this study could provide insights into the most effective thromboprophylaxis strategies for Multiple Myeloma patients, potentially reducing the incidence of venous thromboembolism.
How similar studies have gone: While this study focuses on real-world mapping, similar observational studies have shown promise in understanding treatment efficacy in hematological conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age equal to or greater than 18 years of age. 2. New diagnosis of symptomatic MM according to the CRAB or the SLIM criteria of the International Myeloma Working Group 3. First active treatment for MM started after recruitment in the study 4. Signed informed consent Exclusion Criteria: 1. Patients having had thrombosis within 6 months before diagnosis of MM 2. Patients with need of combined antithrombotic regimens (i.e. VKA or DOAC or LMWK and one or two antiplatelet drugs) 3. Ongoing first active treatment for MM initiated before the starting of the study.
Where it's running
-
Fondazione Policlinico Universitario A. Gemelli IRCCS UOC Servizio e DH di Ematologia
Roma, Italy Recruiting
Study contacts
- Principal investigator: Valerio De Stefano — Università Cattolica, Fondazione Policlinico A. Gemelli IRCCS, Roma
- Study coordinator: Paola Fazi
- Email: p.fazi@gimema.it
- Phone: 0670390528
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI analysis of ECGs to detect structural heart disease
This project will test whether AI can read traditional and wearable ECGs to find undiagnosed valve disease, pulmonary hypertension, and heart failure in adults.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
-
Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma
This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.
-
SMS text check-ins to track symptoms for people with plasma cell disorders
This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.